Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry

Hazar, Volkan; Kesik, Vural; Karasu, Gülsün; Öztürk, Gülyüz; Küpesiz, Alphan; Kılıç, Suar; Ataş, Erman; Uygun, Vedat; Eker, Nurşah; Erbey, Fatih; Bengoa, Şebnem; Emir, Suna; Anak, Sema; Öniz, Haldun; Daloğlu, Hayriye; Aksoylar, Serap; Koçak, Ülker; Karakükçü, Musa; Elli, Murat; Kurucu, Nilgün; Yeşilipek, Akif

doi:10.1080/10428194.2017.1330472

Risk factors predicting the survival of pediatric patients with relapsed/refractory non-Hodgkin lymphoma who underwent hematopoietic stem cell transplantation: a retrospective study from the Turkish pediatric bone marrow transplantation registry

Hazar V., Kesik V., Karasu G. T., Öztürk G., Küpesiz A., Kılıç S. Ç., ...Daha Fazla

Leukemia and Lymphoma, cilt.59, sa.1, ss.85-96, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 59 Sayı: 1
Basım Tarihi: 2018
Doi Numarası: 10.1080/10428194.2017.1330472
Dergi Adı: Leukemia and Lymphoma
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.85-96
Anahtar Kelimeler: children and adolescents, hematopoietic stem cell transplantation, Relapsed or refractory non-Hodgkin lymphoma
Ondokuz Mayıs Üniversitesi Adresli: Evet

Özet

We examined outcomes of 62 pediatric patients with relapsed or refractory non-Hodgkin lymphoma (rr-NHL) who underwent hematopoietic stem cell transplantation (HSCT). The overall survival (OS) and event-free survival (EFS) rates were 65% and 48%, respectively. Survival rates for patients with chemosensitive disease at the time of HSCT were significantly higher than those of patients with chemoresistant disease (69% vs. 37%, p =.019 for OS; 54% vs. 12%, p <.001 for EFS; respectively). A chemoresistant disease at transplantation was the only factor that predicted a limited OS (hazard ratio = 10.00) and EFS (hazard ratio = 16.39) rates. Intensive chemotherapy followed by HSCT could be an effective strategy for treating children with rr-NHL and may offer improved survival for a significant group of pediatric patients, particularly those with chemosensitive disease at transplantation.